Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers ↧ ↧ Dyne, Sarepta shares tumble as Novartis setback weighs on muscle di... Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
published
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers ↧
Open the original public source →
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.